1.46
price up icon1.39%   0.02
pre-market  Vorhandelsmarkt:  1.46  
loading
Schlusskurs vom Vortag:
$1.44
Offen:
$1.43
24-Stunden-Volumen:
385.11K
Relative Volume:
0.16
Marktkapitalisierung:
$15.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-39.14M
KGV:
-0.2446
EPS:
-5.97
Netto-Cashflow:
$-28.20M
1W Leistung:
-10.43%
1M Leistung:
+35.19%
6M Leistung:
-53.65%
1J Leistung:
-93.15%
1-Tages-Spanne:
Value
$1.4009
$1.49
1-Wochen-Bereich:
Value
$1.4009
$1.67
52-Wochen-Spanne:
Value
$0.65
$26.25

Citius Pharmaceuticals Inc Stock (CTXR) Company Profile

Name
Firmenname
Citius Pharmaceuticals Inc
Name
Telefon
(908) 967-6676
Name
Adresse
11 COMMERCE DRIVE, CRANFORD, NJ
Name
Mitarbeiter
23
Name
Twitter
Name
Nächster Verdiensttermin
2025-02-07
Name
Neueste SEC-Einreichungen
Name
CTXR's Discussions on Twitter

Vergleichen Sie CTXR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CTXR
Citius Pharmaceuticals Inc
1.46 18.21M 0 -39.14M -28.20M -5.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-30 Hochstufung D. Boral Capital Hold → Buy
2021-11-30 Eingeleitet Maxim Group Buy

Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten

pulisher
02:20 AM

Is Citius Pharmaceuticals Inc. a good long term investmentSkyrocketing investment returns - Autocar Professional

02:20 AM
pulisher
Jul 22, 2025

What drives Citius Pharmaceuticals Inc. stock priceFree Real-Time Stock Data - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Citius Pharmaceuticals Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

What analysts say about Citius Pharmaceuticals Inc. stockRecord-breaking capital gains - Autocar Professional

Jul 20, 2025
pulisher
Jul 19, 2025

Citius Oncology Announces Closing of $9.0 Million Public Offering - Eastern Progress

Jul 19, 2025
pulisher
Jul 17, 2025

Citius Oncology closes $9 million public offering to support LYMPHIR - Investing.com Australia

Jul 17, 2025
pulisher
Jul 17, 2025

Citius Oncology closes $9 million public offering to support LYMPHIR By Investing.com - Investing.com Nigeria

Jul 17, 2025
pulisher
Jul 17, 2025

Citius Oncology Raises $9M in Public Offering for LYMPHIR Commercialization - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Citius Oncology Announces Closing Of $9.0 Million Public Offering - Barchart.com

Jul 17, 2025
pulisher
Jul 17, 2025

Citius Oncology Announces Pricing Of $9M "Reasonable Best-Efforts" Public Offering Of 6,818,182 Shares Of Common Stock And Warrants To Purchase Shares Of Common Stock At A Public Offering Price Of $1.32 Per Share - 富途牛牛

Jul 17, 2025
pulisher
Jul 17, 2025

Cencora distribution deal boosts Citius shares - MSN

Jul 17, 2025
pulisher
Jul 16, 2025

Citius Pharmaceuticals shares fall 1.34% after-hours following Citius Oncology's public offering. - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Citius Oncology Announces Pricing of $9.0 Million Public Offering - Finansavisen

Jul 16, 2025
pulisher
Jul 15, 2025

Citius Oncology (CTOR): Is LYMPHIR's Launch Priced for Success? - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Citius Oncology: Is A Lymphir Launch Coming Too Late? - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

Citius Pharmaceuticals (CTXR) Surges on New Distribution Deal - GuruFocus

Jul 15, 2025
pulisher
Jul 15, 2025

Citius Oncology stock rises after expanding LYMPHIR distribution network By Investing.com - Investing.com Nigeria

Jul 15, 2025
pulisher
Jul 15, 2025

Citius Oncology stock rises after expanding LYMPHIR distribution network - Investing.com Australia

Jul 15, 2025
pulisher
Jul 15, 2025

Citius Oncology Expands Lymphir Distribution With Cencora - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Citius Oncology expands distribution network for LYMPHIR with Cencora - Investing.com Australia

Jul 15, 2025
pulisher
Jul 15, 2025

Citius Oncology expands distribution network for LYMPHIR with Cencora By Investing.com - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Citius stock gains on Cencora distribution deal (CTXR:NASDAQ) - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

Pre-market Movers: KAPA, CYCC, SONN, RANI... - RTTNews

Jul 15, 2025
pulisher
Jul 15, 2025

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora - Finansavisen

Jul 15, 2025
pulisher
Jul 15, 2025

Citius Pharmaceuticals Soars 10.18% on Nasdaq Compliance - AInvest

Jul 15, 2025
pulisher
Jul 14, 2025

Citius Pharmaceuticals' Strategic Financing: Balancing Dilution Risks with LYMPHIR's Commercial Potential - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Citius Oncology Plans Stock Offering; Shares Down - MarketScreener

Jul 14, 2025
pulisher
Jul 11, 2025

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) On The Verge Of Breaking Even - simplywall.st

Jul 11, 2025
pulisher
Jul 10, 2025

Citius Pharmaceuticals regains Nasdaq compliance - MSN

Jul 10, 2025
pulisher
Jul 09, 2025

Citius Pharmaceuticals Regains Nasdaq Compliance - The Globe and Mail

Jul 09, 2025
pulisher
Jul 08, 2025

CTXR SEC FilingsCitius Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 08, 2025
pulisher
Jul 08, 2025

Citius Pharmaceuticals regains Nasdaq compliance after 10-day streak - Investing.com

Jul 08, 2025
pulisher
Jul 08, 2025

Citius Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement - 富途牛牛

Jul 08, 2025
pulisher
Jul 08, 2025

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - Finansavisen

Jul 08, 2025
pulisher
Jul 06, 2025

Citius Pharmaceuticals: LYMPHIR Launch Ignites High-Growth Potential in CTCL Market - AInvest

Jul 06, 2025
pulisher
Jul 06, 2025

Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR - Insider Monkey

Jul 06, 2025
pulisher
Jun 30, 2025

Citius Pharmaceuticals (CTXR) Receives Buy Rating from Analyst | CTXR Stock News - GuruFocus

Jun 30, 2025
pulisher
Jun 25, 2025

Is Citius Pharmaceuticals, Inc. technically bullish or bearish? - MarketsMojo

Jun 25, 2025
pulisher
Jun 24, 2025

Citius Oncology Stock Soars 10% on LYMPHIR™ Launch Anticipation - AInvest

Jun 24, 2025
pulisher
Jun 23, 2025

Pre-market Movers: INDP, IBO, CDTX, FBRX... - RTTNews

Jun 23, 2025
pulisher
Jun 17, 2025

Citius Oncology prepares for lymphoma treatment launch in 2025 By Investing.com - Investing.com Nigeria

Jun 17, 2025

Finanzdaten der Citius Pharmaceuticals Inc-Aktie (CTXR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):